Loading filters...
Publications per Year (2108 total)
5
1990
2
·
6
·
3
·
3
·
3
1995
8
·
1
·
6
·
8
·
9
2000
17
·
15
·
22
·
27
·
31
2005
31
·
53
·
56
·
81
·
86
2010
102
·
92
·
90
·
110
·
130
2015
105
·
120
·
123
·
92
·
93
2020
99
·
91
·
107
·
103
·
138
2025
40
·
Loaded
Click to load
50 / 2108 papers loaded(scroll for more)
202640 papers
GeneralAll Stages2026
PTBP1 knockdown reprograms glioma stem cells into neuronal-like cells and suppresses tumorigenesis via the DUSP5-ERK1/2 signaling pathway.
Li C et al. Neuro Oncol. 2026
Generalearly2026
NT-I7, a long-acting interleukin-7, increases lymphocyte counts and induces CD8+ T cell clonotype expansion in patients with newly diagnosed high-grade gliomas.
Butt OH et al. Clin Cancer Res. 2026
Generalearly2026
Survival and function in elderly patients with GBM: the role of surgical resection with contemporary multimodal therapy.
Song R et al. J Neurooncol. 2026
AntiangiogenicAll Stages2026
Framework for statistical parametric mapping of the interactions between glioblastoma location, treatment, prognostic variables, and survival using a phase III trial.
Sanvito F et al. Clin Cancer Res. 2026
MGMT methylatedAll Stages2026
DNA Methylation Profiling Reveals a Novel Subtype Harboring IDH Mutation in H3-altered Gliomas.
Fu M et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
Endogenous immune recruitment in glioblastoma CAR T therapy: cytokine, myeloid, and chemokine circuitry.
Liu J et al. J Neurooncol. 2026
GeneralAll Stages2026
MGMT downregulation by CRISPR/Cas13 RNA-guided RNA targeting enhances glioma cell sensitivity to TMZ chemotherapy.
Prins TJ et al. J Neurooncol. 2026
GeneralAll Stages2026
STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.
Colman H et al. J Clin Oncol. 2026
MGMT methylatedAll Stages2026
Glioblastoma survival in rural America: a 10-year experience from a quaternary care center.
Pack E et al. J Neurooncol. 2026
Generalearly2026
Clinical Outcomes and Prognostic Features of Diffuse Hemispheric Glioma, H3 G34-mutant: An International Multi-Institutional Study.
Crowell C et al. Clin Cancer Res. 2026
Immunotherapyearly2026
Immune checkpoint inhibitors in pediatric central nervous system tumors: biology, clinical experience, and translational pathways to precision immunotherapy.
Yenidogan I et al. J Neurooncol. 2026
GeneralAll Stages2026
Pediatric H3 G34-mutant diffuse hemispheric glioma: clinical, imaging and molecular prognostic factors, MGMT expression, and temozolomide response.
Tlais D et al. Acta Neuropathol. 2026
ImmunotherapyAll Stages2026
Glioblastoma immunotherapy in the context of the aging immune system: a systematic review and meta-analysis.
Shireman JM et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
Extracellular vesicles as liquid biopsy tools for personalized therapeutic goals in glioblastoma.
Menaceur Vandenbroucke C et al. Brain. 2026
ImmunotherapyAll Stages2026
Deciphering the tumor microenvironment and role of immunotherapy in Diffuse Midline Glioma: a scoping review.
Ramsoomair CK et al. Neuro Oncol. 2026
Immunotherapyadvanced2026
Preclinical efficacy of combinatorial B7-H3 CAR T cells and ONC206 against diffuse intrinsic pontine glioma.
Timpanaro A et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
YBX1&YBX3 as novel targets to potentiate immune checkpoint blockade response in gliomas.
Ali H et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
De novo H3.3K27M-altered diffuse midline glioma in human brainstem organoids to dissect GD2 CAR T cell function.
Bessler N et al. Nat Cancer. 2026
ImmunotherapyAll Stages2026
TIGIT expression dictates the immunosuppressive reprogramming of myeloid cells in glioblastoma.
Asad M et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
Distinct tumor immune microenvironmental (TIME) landscapes drive divergent immunotherapy responses in glioblastoma.
Weng L et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
Multi-omic landscape of human gliomas from diagnosis to treatment and recurrence.
Piyadasa H et al. Cancer Cell. 2026
ImmunotherapyAll Stages2026
Vaccine therapy for pediatric high-grade glioma: current landscape, challenges, and future directions.
Harper SD et al. J Neurooncol. 2026
ImmunotherapyAll Stages2026
Single-cell profiling of peripheral and local immune compartments reveal unique genotype-independent prognostic immune signatures across isocitrate dehydrogenase-stratified glioma.
Sussman JH et al. Neuro Oncol. 2026
IDH mutantAll Stages2026
Long-term administration of the mutant IDH inhibitor DS-1001b suppresses the growth of IDH1-mutant glioma in vitro and in mouse xenograft models and alters epigenetic profiles.
Fujimoto K et al. Acta Neuropathol. 2026
MGMT methylatedearly2026
Maximal resection improves survival in MGMT methylated very elderly glioblastoma patients.
Jankovic D et al. J Neurooncol. 2026
IDH mutantadvanced2026
18F-DOPA-PET and advanced MRI improve treatment response assessment in IDH1/2-mutant gliomas treated with IDH inhibitors.
Prost D et al. Clin Cancer Res. 2026
GeneralAll Stages2026
ETC-501 is a Brain Penetrant MNK Kinase Inhibitor that Potentiates TMZ-Induced Senescence and Sensitizes Glioblastoma Cells to Senolytic Therapy.
Nah GSS et al. Cancer Res. 2026
Generaladvanced2026
Investigation of the effects of radiotherapy and chemotherapy on brain volume in cancer patients: brain tumor study.
Deniz B et al. J Neurooncol. 2026
Generaladvanced2026
Spatial Transcriptomics Characterisation of Radionecrotic Changes in Glioblastoma Patients.
Seferbekova Z et al. Neuro Oncol. 2026
Generalearly2026
Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.
van den Bent MJ et al. Lancet Oncol. 2026
ImmunotherapyAll Stages2026
Clinical and translational progress in oncolytic virotherapy for pediatric CNS tumors.
Elgehiny A et al. J Neurooncol. 2026
Generalearly2026
Prognostic role of delta radiomics in pediatric pontine diffuse midline gliomas.
Bıyıklı E et al. J Neurooncol. 2026
GeneralAll Stages2026
Rate of biopsy prior to resection among patients with high-grade glioma: a nationwide database analysis.
Howard SD et al. J Neurosurg. 2026
GeneralAll Stages2026
Clinical Implications of Aberrant Retinoblastoma Signaling in Patients With Grade 4 IDH-Mutant Astrocytoma: A Retrospective Cohort Study.
Maqbool MA et al. Neurology. 2026
MGMT methylatedadvanced2026
Association of proton pump inhibitor use with outcome of patients with recurrent glioblastoma.
Le Rhun E et al. Eur J Cancer. 2026
MGMT methylatedearly2026
Tumor treating fields for newly diagnosed glioblastoma: a retrospective analysis.
Wang C et al. J Neurooncol. 2026
MGMT methylatedAll Stages2026
Early distant progression in adult Histone-3 K27-altered diffuse midline gliomas.
Grassl N et al. J Neurooncol. 2026
MGMT methylatedAll Stages2026
DNA damage response profile distinguishes poor-acting gliomas with shared methylome signatures.
Leelatian N et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
SPP1+ macrophages polarized by lactate confer the progression of hypoxic adaptive tumor cells in brain.
Zhang J et al. Neuro Oncol. 2026
ImmunotherapyAll Stages2026
Male-biased Yap1-Cd276/B7-H3 axis for immune evasion in medulloblastoma.
Abdelfattah N et al. Cancer Cell. 2026
202310 papers
MGMT methylatedAll Stages2023
Patterns, predictors and prognostic relevance of high-grade hematotoxicity after temozolomide or temozolomide-lomustine in the CeTeG/NOA-09 trial.
Weller J et al. J Neurooncol. 2023
MGMT methylatedAll Stages2023
Early ependymal tumor with MN1-BEND2 fusion: a mostly cerebral tumor of female children with a good prognosis that is distinct from classical astroblastoma.
Lehman NL et al. J Neurooncol. 2023
AntiangiogenicAll Stages2023
Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma.
Ellingson BM et al. Clin Cancer Res. 2023
MGMT methylatedearly2023
Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
Fishman H et al. J Neurooncol. 2023
MGMT methylatedAll Stages2023
Brain radiotoxicity-related 15CAcBRT gene expression signature predicts survival prognosis of glioblastoma patients.
Reyes-González J et al. Neuro Oncol. 2023
MGMT methylatedAll Stages2023
Deep DNA sequencing of MGMT, TP53 and AGT in Mexican astrocytoma patients identifies an excess of genetic variants in women and a predictive biomarker.
Carlos-Escalante JA et al. J Neurooncol. 2023
MGMT methylatedAll Stages2023
Adult intracranial ependymoma-relevance of DNA methylation profiling for diagnosis, prognosis, and treatment.
Träger M et al. Neuro Oncol. 2023
MGMT methylatedAll Stages2023
Predicting glioblastoma molecular subtypes and prognosis with a multimodal model integrating convolutional neural network, radiomics, and semantics.
Zhong S et al. J Neurosurg. 2023
MGMT methylatedAll Stages2023
Low expression of Ki-67/MIB-1 labeling index in IDH wild type glioblastoma predicts prolonged survival independently by MGMT methylation status.
Tini P et al. J Neurooncol. 2023
MGMT methylatedAll Stages2023
Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ntafoulis I et al. Br J Cancer. 2023